A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Recruiting · Phase 1, Phase 2 · NCT06697184
Conditions: Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
At a glance
- Research payments reported, 2025
- $3.0M
- U.S. investigators named
- 6
- Sites paid
- 10
- Planned or actual enrollment
- 258
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Sonrotoclax (drug), Zanubrutinib (drug)
- Dates
- Started 2025-01-23; completion 2032-11-30
- Results posted
- Not yet
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $3.0M in research payments for this study in 2025 (40 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Yumeng Zhang Hematology & Oncology · Tampa, FL
- Sunil Babu, M.D. Medical Oncology · Fort Wayne, IN
- Marc S. Hoffmann, MD Hematology & Oncology · Overland Park, KS
- Matthew S. Davids, M.D. Hematology & Oncology · Boston, MA
- Brad S. Kahl, MD Medical Oncology · Saint Louis, MO
- Mazyar Shadman, MD,MPH Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Kansas Cancer Center $871,936
- Dana-Farber Cancer Institute $637,184
- Washington University School of Medicine Siteman Cancer Center $603,648
- H. Lee Moffitt Cancer Center Foundation $536,576
- Fort Wayne Medical Oncology and Hematology $123,228
- Washington University $78,760
- Fred Hutchinson Cancer Research Center $75,456
- Dana Farber Mass General Brigham Cancer Care Inc $49,538
- Fred Hutchinson Cancer Center $41,660
- Moffitt Cancer Center $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.